{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:36:42Z","timestamp":1790707002190,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.euo.2024.12.013","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T16:18:36Z","timestamp":1738081116000},"page":"571-580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Systematic Review and Meta-analysis of the Clinical Impact of Prophylactic Quinolones with Adjuvant Bacillus Calmette-Gu\u00e9rin Instillation for Non\u2013muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"8","author":[{"given":"Chris Ho-Ming","family":"Wong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Ching-Ho","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Ka-Wai","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffi Kar-Kei","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Siu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Birtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otakar","family":"Capoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L.","family":"Dom\u00ednguez-Escrig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paramananthan","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhavan P.","family":"Rai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bas W.G.","family":"van Rhijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh F.","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos N.","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Gontero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy Yuen-Chun","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2024.12.013_b0005","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","article-title":"Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice","volume":"20","author":"van Hoogstraten","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.euo.2024.12.013_b0010","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.eururo.2020.09.006","article-title":"Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita","volume":"78","author":"Teoh","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0015","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.eururo.2020.12.033","article-title":"European Association of Urology (EAU) prognostic factor risk groups for non\u2013muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004\/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel","volume":"79","author":"Sylvester","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0020","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non\u2013muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Babjuk","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0025","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1464-410x.2001.02306.x","article-title":"A systematic review of intravesical bacillus Calmette-Guerin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer","volume":"88","author":"Shelley","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.12.013_b0035","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0040","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"Bohle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.12.013_b0045","first-page":"765","article-title":"Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis","volume":"21","author":"Huncharek","year":"2001","journal-title":"Anticancer Res"},{"key":"10.1016\/j.euo.2024.12.013_b0050","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","article-title":"Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials","volume":"168","author":"Sylvester","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0055","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","volume":"57","author":"Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0060","article-title":"Intravesical bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer","volume":"2011","author":"Shang","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.euo.2024.12.013_b0065","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol Clin North Am"},{"key":"10.1016\/j.euo.2024.12.013_b0070","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0022-5347(05)67974-8","article-title":"Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results","volume":"163","author":"Losa","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0075","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1016\/S0022-5347(05)64994-4","article-title":"Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance","volume":"167","author":"Griffiths","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0080","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1442-2042.2008.02012.x","article-title":"Clinical outcomes of bacillus Calmette-Guerin instillation therapy for carcinoma in situ of urinary bladder","volume":"15","author":"Takenaka","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0085","first-page":"157","article-title":"Managing the adverse events of intravesical bacillus Calmette-Guerin therapy","volume":"7","author":"Decaestecker","year":"2015","journal-title":"Res Rep Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0090","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"issue":"Suppl 1","key":"10.1016\/j.euo.2024.12.013_b0095","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000052378","article-title":"Sensitivity of BCG to modern antibiotics","volume":"37","author":"Durek","year":"2000","journal-title":"Eur Urol."},{"key":"10.1016\/j.euo.2024.12.013_b0100","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1128\/AAC.44.2.283-286.2000","article-title":"Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex","volume":"44","author":"Tomioka","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.euo.2024.12.013_b0105","article-title":"Antibiotic therapy impact on intravesical BCG therapy efficacy for high-risk localized bladder cancer treatment","volume":"13","author":"Aubert","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.euo.2024.12.013_b0110","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S0090-4295(00)01117-1","article-title":"Tolerability of bacille Calmette-Guerin maintenance therapy for superficial bladder cancer","volume":"57","author":"Saint","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.12.013_b0115","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.juro.2006.04.104","article-title":"The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study","volume":"176","author":"Colombel","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0120","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1464-410X.2009.08469.x","article-title":"Short-term administration of prulifloxacin in patients with nonmuscle-invasive bladder cancer: an effective option for the prevention of bacillus Calmette-Guerin-induced toxicity?","volume":"104","author":"Damiano","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.12.013_b0125","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.euf.2022.06.002","article-title":"Effect of levofloxacin on the efficacy and adverse events in intravesical bacillus Calmette-Guerin treatment for bladder cancer: results of a randomized, prospective, multicenter study","volume":"8","author":"Numakura","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2024.12.013_b0130","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1177\/039156031007700403","article-title":"[Prevention of topic toxicity of BCG with single-dose prulifloxacin. Preliminary results of a randomized pilot study]","volume":"77","author":"Serretta","year":"2010","journal-title":"Urologia"},{"issue":"4 Suppl","key":"10.1016\/j.euo.2024.12.013_b0135","article-title":"The effect of levofloxacin on bacillus Calmette-Guerin induced toxicity in patients with nonmuscleinvasive bladder cancer: results of a randomized, prospective, multicenter study","volume":"195","author":"Numakura","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0140","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0145","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0150","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.juro.2016.12.090","article-title":"Intravesical therapy for the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-analysis","volume":"197","author":"Chou","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0155","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.12.013_b0160","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0165","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.urology.2007.07.017","article-title":"The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma","volume":"70","author":"Agrawal","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.euo.2024.12.013_b0170","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000008300","article-title":"Dose, duration and strain of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: Meta-analysis of randomized clinical trials","volume":"96","author":"Quan","year":"2017","journal-title":"Medicine"},{"key":"10.1016\/j.euo.2024.12.013_b0175","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0022-5347(05)65966-6","volume":"166","author":"van der Meijden","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0180","article-title":"Intravesical bacillus Calmette-Guerin (BCG) treatment\u2019s severe complications: a single institution review of incidence, presentation and treatment outcome","volume":"19","author":"Waked","year":"2020","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.euo.2024.12.013_b0185","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0022-5347(05)64751-9","article-title":"Optimal treatment of systemic bacillus Calmette-Guerin infection: investigations in an animal model","volume":"168","author":"Durek","year":"2002","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2024.12.013_b0190","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/jac\/34.3.343","article-title":"In-vitro activity of quinolones and macrolides against mycobacteria","volume":"34","author":"Yew","year":"1994","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.euo.2024.12.013_b0195","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.urolonc.2023.04.003","article-title":"The efficacy and safety outcomes of lower dose BCG compared to intravesical chemotherapy in non-muscle-invasive bladder cancer: a network meta-analysis","volume":"41","author":"Kawada","year":"2023","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2024.12.013_b0200","doi-asserted-by":"crossref","first-page":"161","DOI":"10.18773\/austprescr.2021.035","article-title":"Fluoroquinolone antibiotics and adverse events","volume":"44","author":"Baggio","year":"2021","journal-title":"Aust Prescr"},{"key":"10.1016\/j.euo.2024.12.013_b0205","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bju.16303","article-title":"Cumulative incidence of and risk factors for BCG infection after adjuvant BCG instillations","volume":"134","author":"Holmberg","year":"2024","journal-title":"BJU Int"},{"key":"10.1016\/j.euo.2024.12.013_b0210","doi-asserted-by":"crossref","first-page":"105","DOI":"10.11604\/pamj.2015.21.105.5469","article-title":"Resistance pattern of Enterobacteriaceae isolates from urinary tract infections to selected quinolones in Yaounde","volume":"21","author":"Lyonga","year":"2015","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.euo.2024.12.013_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110393","article-title":"Mechanisms of BCG in the treatment of bladder cancer-current understanding and the prospect","volume":"129","author":"Han","year":"2020","journal-title":"Biomed Pharmacother"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931124002967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:25:30Z","timestamp":1762629930000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931124002967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2588931124002967"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2024.12.013","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review and Meta-analysis of the Clinical Impact of Prophylactic Quinolones with Adjuvant Bacillus Calmette-Gu\u00e9rin Instillation for Non\u2013muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2024.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}